SequelSEC

Inhibikase Therapeutics, Inc. IKT

Biological Products, (No Diagnostic Substances) · CIK 0001750149 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2024-12-31
Operating income
-$28.59M
Fiscal year ended 2024-12-31
Free cash flow
-$19.15M
Fiscal year ended 2024-12-31

Inhibikase Therapeutics, Inc. (IKT) reported revenue of $0 and net income of -$27.52M for the fiscal year ended 2024-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Inhibikase Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Inhibikase Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$0$260.50K$123.44K$3.10M$698.47K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$28.59M-$20.09M-$18.13M-$14.77M-$2.82M
Net income-$27.52M-$19.03M-$18.05M-$14.79M-$2.85M
Research & development$17.21M$13.62M$12.03M$11.36M$893.80K
Weighted-average diluted sharesshares 23.71Mshares 6.03Mshares 4.22Mshares 18.21MUnavailable
Pretax income-$27.52KUnavailableUnavailableUnavailableUnavailable
Income tax expense$0UnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.16$-3.16$-4.28$-0.81Unavailable
Selling, general & administrative$11.38M$6.73M$6.22M$6.51M$2.62M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Inhibikase Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$97.50M$9.20M$7.19M$40.75MUnavailable
Total assets$98.60M$14.51M$24.94M$42.47M$14.78M
Current assets$98.45M$14.21M$24.37M$42.47M$14.78M
Total liabilities$3.73M$3.53M$3.90M$4.05M$5.00M
Current liabilities$3.73M$3.44M$3.70M$4.05M$4.72M
Total equity incl. NCI$94.87M$10.98M$21.04M$38.42M$9.78M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailable$381.78KUnavailable$248.91KUnavailable
Accounts payable$943.02K$646.77K$1.15M$1.09M$1.72M

Cash flow

Inhibikase Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$19.15M-$18.09M-$17.35M-$14.30M-$1.13M
Capital expenditures$0$14.24K$243.26K$0Unavailable
Investing cash flow-$37.00M$11.66M-$16.01M$0Unavailable
Financing cash flow$103.48M$8.41M-$204.77K$41.09M$15.06M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$8.14M$500.15K$458.15K$1.53M$573.70K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Inhibikase Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$19.15M-$18.10M-$17.59M-$14.30MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-7712.0%-14686.2%-476.2%-403.5%
FCF marginUnavailable-6947.9%-14253.4%-461.1%Unavailable
SBC / revenueUnavailable192.0%371.1%49.4%82.1%
Current ratio26.37x4.13x6.59x10.47xUnavailable
Revenue YoY growth-100.0%111.0%-96.0%343.9%Unavailable
Net marginUnavailable-7304.7%-14625.9%-476.9%-407.7%
R&D / revenueUnavailable5227.8%9749.7%366.4%128.0%
CapEx / revenueUnavailable5.5%197.1%0.0%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IKT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.